We are live on ! Find out more
SCM

Silverarc Capital Management Portfolio holdings

AUM $980M
1-Year Est. Return 470.8%
This Fund
S&P 500
This Quarter Est. Return
+18.72%
1 Year Est. Return
+470.8%
3 Year Est. Return
+3,352.06%
5 Year Est. Return
+7,957.7%
10 Year Est. Return
–
AUM
$445M
AUM Growth
+$21.4M
Cap. Flow
-$18.8M
Cap. Flow %
-4.22%
Top 10 Hldgs %
46.96%
Holding
84
New
14
Increased
27
Reduced
18
Closed
13

Top Buys

Rank Stock Value
1
INSM icon
Insmed
INSM
+$15.3M
2
CNTA
Centessa Pharmaceuticals
CNTA
+$9.12M
3
PTGX icon
Protagonist Therapeutics
PTGX
+$5.93M
4
VCYT icon
Veracyte
VCYT
+$5.3M
5
PCVX icon
Vaxcyte
PCVX
+$5.23M

Top Sells

Rank Stock Value
1
MORF
Morphic Holding, Inc. Common Stock
MORF
+$16.6M
2
CRBP icon
Corbus Pharmaceuticals
CRBP
+$8.83M
3
CLDX icon
Celldex Therapeutics
CLDX
+$8.76M
4
NUVL
Nuvalent
NUVL
+$7.82M
5
URGN icon
UroGen Pharma
URGN
+$2.98M

Sector Composition

Rank Sector Weight
1 Healthcare 99.65%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INSM icon
76
CALL
Insmed
INSM
$21.2B
– –
-250,000
Closed -$16.8M
JSPR icon
77
Jasper Therapeutics
JSPR
$19.8M
– –
-109,892
Closed -$2.49M
MGNX icon
78
MacroGenics
MGNX
$237M
– –
-370,000
Closed -$1.57M
MIRM icon
79
Mirum Pharmaceuticals
MIRM
$6.61B
– –
-79,194
Closed -$2.71M
RLMD icon
80
Relmada Therapeutics
RLMD
$551M
– –
-99,379
Closed -$298K
SLNO
81
DELISTED
Soleno Therapeutics
SLNO
– –
-15,000
Closed -$612K
STOK icon
82
Stoke Therapeutics
STOK
$1.81B
– –
-141,518
Closed -$1.91M
ZURA icon
83
Zura Bio
ZURA
$512M
– –
-328,504
Closed -$1.15M
MORF
84
DELISTED
Morphic Holding, Inc. Common Stock
MORF
– –
-486,306
Closed -$16.6M
1 2 3
4

Similar funds

BIP
Blueprint Investment Partners Greensboro, North Carolina $980M AUM 27.19% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $977M AUM 19.09% 1-Year Est. Return
FCM
Fortis Capital Management Bellevue, Washington $977M AUM 17.17% 1-Year Est. Return
KL
KIM LLC Wichita, Kansas $976M AUM 0.91% 1-Year Est. Return
GFP
Gryphon Financial Partners Columbus, Ohio $976M AUM 23.05% 1-Year Est. Return
ADIC
Abu Dhabi Investment Council Abu Dhabi, United Arab Emirates $975M AUM
PCM
Politan Capital Management New York $985M AUM 3.12% 1-Year Est. Return

Silverarc Capital Management's Q3 2024 Portfolio in Review

As of Q3 2024, Silverarc Capital Management held 84 positions worth $445M, up 5.1% from $424M the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Silverarc Capital Management withdrew a net $18.8M in Q3 2024, closing 13 positions and reducing 18 holdings. Its most notable exit was Morphic Holding, Inc. Common Stock, an estimated $16.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 96% a quarter earlier.

Against the trend, Silverarc Capital Management opened a new position in Centessa Pharmaceuticals worth $11.9M.

  • Silverarc Capital Management's largest Q3 2024 buy was Centessa Pharmaceuticals: 744,592 shares worth $11.9M.
  • Silverarc Capital Management added most to Insmed in Q3 2024, an estimated $15.3M increase.
  • Silverarc Capital Management's biggest Q3 2024 reduction was Celldex Therapeutics, cutting an estimated $8.76M.
  • Silverarc Capital Management fully exited Morphic Holding, Inc. Common Stock in Q3 2024, selling an estimated $16.6M.
  • Silverarc Capital Management's ten largest holdings make up 47% of its $445M portfolio in Q3 2024.
  • Silverarc Capital Management opened 14 new positions and closed 13 in Q3 2024.
  • Silverarc Capital Management's portfolio value rose 5.1% quarter-over-quarter to $445M.

Based on Silverarc Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.